JAK tyrosine kinase inhibitors (Portola)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameJAK tyrosine kinase inhibitors (Portola)
Drug Alias NameJAK2, JAK3 and JAK3/1 inhibitors (Portola)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3Tyrosine-protein kinase JAK1
Therapy Area/IndicationsInflammationMyelodysplastic Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPortola Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPortola Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInflammationMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A